Articles From: Gilead, CVS strike deal on Hepatitis C drugs to 'Birdman' wins four Oscars, including best picture


2015/1/5
By Russ Britt, MarketWatch Retail giant to focus on biotech firm's $1,000-a-day pills LOS ANGELES (MarketWatch) -- Shares of Gilead Sciences Inc. were up more than 2% Monday after the biotechnology giant scored an exclusive rights deal with the nation's largest drug-store chain, CVS Health Corp., for two Hepatitis C treatments that cost $1,000 per pill or more.
Sign-up for Gilead, CVS strike deal on Hepatitis C drugs investment picks
2015/1/2
By Russ Britt, MarketWatch Other attempts at cost control having minimal effect on system This is the last installment in a four-part series.
Sign-up for UPDATE: Health-care costs: It's time for patients to take control investment picks
2015/1/2
By Russ Britt, MarketWatch Patients face more pressure to plan for medical expenses This is the first installment in a four-part series.
Sign-up for UPDATE: Why your medical bills will just keep growing investment picks
2015/1/12
By Russ Britt, MarketWatch Awards given as filmdom deals with attempts to suppress media LOS ANGELES (MarketWatch) -- "Boyhood," a drama that took 12 years to film but only cost $4 million to produce, took top honors Sunday at the 72nd annual Golden Globe Awards, on a night when Hollywood came to grips with several recent notable attempts to suppress free expression.
Sign-up for UPDATE: 'Boyhood' wins Golden Globe for best drama investment picks
2015/1/12
By Russ Britt, MarketWatch Awards given as filmdom deals with attempts to suppress media LOS ANGELES (MarketWatch) -- "Boyhood," a drama that took 12 years to film but only cost $4 million to produce, took top honors Sunday at the 72nd annual Golden Globe Awards, on a night when Hollywood came to grips with several recent notable attempts to suppress free expression.
Sign-up for 'Boyhood' wins Golden Globe for best drama investment picks
2015/1/8
By Russ Britt, MarketWatch Boston Scientific turning around, up more than 4% on upgrade LOS ANGELES (MarketWatch)-- A slew of stock upgrades, improved outlooks, positive drug trials and an overall market rally boosted the health-care sector Thursday.
Sign-up for Drug trials, upgrades boost health-care sector investment picks
2014/12/19
By Russ Britt, MarketWatch Conservatives, liberals both call for action after movie axed LOS ANGELES (MarketWatch)--Michael Moore and Newt Gingrich, voicing the same sentiment.
Sign-up for UPDATE: North Korea brokers peace between Republicans and Democrats investment picks
2014/12/19
By Russ Britt, MarketWatch Conservatives, liberals both call for action after movie axed LOS ANGELES (MarketWatch)--Michael Moore and Newt Gingrich, voicing the same sentiment.
Sign-up for UPDATE: The one thing Republicans and Democrats actually agree about: North Korea investment picks
2014/12/18
By Russ Britt, MarketWatch Conservatives, liberals both call for action after movie axed LOS ANGELES (MarketWatch)--Michael Moore and Newt Gingrich, voicing the same sentiment.
Sign-up for Strange bedfellows show up in Sony hacking investment picks
2014/12/18
By Russ Britt, MarketWatch Finding comes as studio cancels debut of 'The Interview' LOS ANGELES (MarketWatch) -- The hacking of Sony Corp.'s movie-making unit was elevated from corporate espionage to international incident Wednesday as sources told various news organizations that North Korea appears to be behind the attack on the film studio.
Sign-up for UPDATE: North Korea behind Sony attacks, reports say investment picks
2014/12/17
By Russ Britt, MarketWatch Finding comes as studio cancels debut of 'The Interview' The hacking of Sony Corp.'s movie-making unit was elevated from corporate espionage to international incident Wednesday as sources told various news organizations that North Korea appears to be behind the attack on the film studio.
Sign-up for UPDATE: North Korea behind Sony attacks, reports say investment picks
2014/12/17
By Russ Britt, MarketWatch Studio follows lead of theater owners who delay its release Sony Pictures Entertainment will cancel its planned Christmas Day release of "The Interview," the subject of recent hack attacks and violent threats against the company and theater owners, the studio said Wednesday.
Sign-up for UPDATE: Sony cancels Christmas debut of 'The Interview' investment picks
2014/12/17
By Russ Britt, MarketWatch Studio follows lead of theater owners who delay its release Sony Pictures Entertainment will cancel its planned Christmas Day release of "The Interview," the subject of recent hack attacks and violent threats against the company and theater owners, the studio said Wednesday.
Sign-up for Sony cancels Christmas debut of 'The Interview' investment picks
2014/12/17
By Russ Britt, MarketWatch Process used to inactivate pathogens prior to transfusions LOS ANGELES (MarketWatch) -- Shares of tiny biomedical products company Cerus Corp.
Sign-up for Cerus jumps on FDA OK for plasma treatment investment picks
2015/1/16
By Russ Britt, MarketWatch Tavenner to leave as head of Centers for Medicare and Medicaid Marilyn Tavenner, who oversaw the Centers for Medicare and Medicaid during one of the most tumultuous periods in its history, is stepping down as the agency's administrator, the agency said Friday.
Sign-up for Official who oversaw rocky Obamacare rollout is stepping down investment picks
2015/1/29
By Russ Britt, MarketWatch Seven of last 10 reports have fallen short of Wall Street views LOS ANGELES (MarketWatch) -- Amazon.com Inc. investors are bracing themselves for what has become a quarterly roll of the dice, as they wonder whether the online retailer will disappoint them yet again when it reports earnings after the market close on Thursday.
Sign-up for Amazon investors roll the dice on earnings investment picks
2015/1/30
By Russ Britt, MarketWatch Earnings, FDA ruling come into play for biopharmas LOS ANGELES (MarketWatch)--Two drug maker stocks posted double-digit gains on Friday as Biogen Idec Inc. surged on a strong earnings report and Intercept Pharmaceuticals Inc. won a critical ruling from the U.S. Food and Drug Administration.
Sign-up for Biogen, Intercept post double-digit gains investment picks
2015/2/2
By Russ Britt, MarketWatch Company says drug proved 100% effective in lab mice tests LOS ANGELES (MarketWatch) -- A tiny biotechnology company said Monday that it just may have an effective treatment for the deadly Ebola virus.
Sign-up for Tiny biotech says it may have an answer for Ebola investment picks
2015/2/2
By Russ Britt, MarketWatch Boosted internal forecasts, high outside praise play a role LOS ANGELES (MarketWatch) -- When HCA Holdings Inc. reports earnings early Tuesday, one thing to watch for in addition to fourth-quarter results will be whether the nation's biggest hospital chain can live up to its own raised expectations and the praise it received from outsiders last month.
Sign-up for What to look for in HCA earnings investment picks
2015/2/2
By Russ Britt, MarketWatch $1,000-a-day hepatitis C drugs figure prominently in results It's probably a foregone conclusion that anyone who has even heard of Gilead Sciences Inc. will be watching to see how the biotechnology company's sales of its hit hepatitis C drugs did when it reports fourth-quarter earnings after the close Tuesday.
Sign-up for What to look for in Gilead earnings investment picks
2015/2/4
By Russ Britt, MarketWatch Shares drop as investors fear high margins will come to an end LOS ANGELES (MarketWatch)--The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.
Sign-up for Gilead to discount its pricey Sovaldi drug investment picks
2015/2/3
By Russ Britt, MarketWatch $1,000-a-day hepatitis C drugs figure prominently in results It's probably a foregone conclusion that anyone who has even heard of Gilead Sciences Inc. will be watching to see how the biotechnology company's sales of its hit hepatitis C drugs did when it reports fourth-quarter earnings after the close Tuesday.
Sign-up for UPDATE: What to look for in Gilead earnings investment picks
2015/2/4
By Russ Britt, MarketWatch Shares drop as investors fear high margins will come to an end LOS ANGELES (MarketWatch)--The future appeared golden when Gilead Sciences Inc. reported its results Tuesday, with earnings per share blowing past forecasts and revenue beating estimates by more than half a billion dollars.
Sign-up for UPDATE: Gilead to discount its pricey Sovaldi drug investment picks
2015/2/3
By Russ Britt, MarketWatch Measles outbreak not expected to slow entertainment giant A measles outbreak at its California resort notwithstanding, the earnings juggernaut that is Walt Disney Co.
Sign-up for UPDATE: What to look for in Disney earnings investment picks
2015/1/27
By Russ Britt, MarketWatch Drug giant overcomes patent woes and beats forecasts LOS ANGELES (MarketWatch) -- While the rest of the market was sinking, shares of drug giant Pfizer Inc. managed to eke out gains early Tuesday after Wall Street decided the company's fourth-quarter results were more critical than its 2015 projections.
Sign-up for Pfizer ekes out gains on a down market day investment picks
2015/2/24
By Russ Britt, MarketWatch Street watches for seventh straight upside surprise from company LOS ANGELES (MarketWatch) -- Investors will be watching to see if Cablevision Systems Corp.
Sign-up for What to look for in Cablevision earnings investment picks
2015/2/23
By Russ Britt, MarketWatch Market sees starting point in negotiations as positive for sector When is a loss a gain?
Sign-up for Proposed Medicare loss is a gain for insurers investment picks
2015/2/23
By Russ Britt, MarketWatch Deal is just above Friday closing price; Salix shares stumble LOS ANGELES (MarketWatch) -- Shares of Valeant Pharmaceuticals International Inc. soared by more than 14% at one point in morning trades Monday after the drug company said it was buying Salix Pharmaceuticals Ltd.
Sign-up for Valeant soars on plan to buy Salix for $10 billion investment picks
2015/2/23
By Russ Britt, MarketWatch Moore, Redmayne are top actors; 'Budapest' wins four awards LOS ANGELES (MarketWatch) -- "Birdman," the quirky tale of a Hollywood action hero's attempt to make a comeback via the Broadway stage, was declared the best picture of 2014 at Sunday's Academy Awards, taking four prizes in all and eking out a victory over "Boyhood." Eddie Redmayne, the British actor who took on the role of ALS-afflicted physicist Stephen Hawking, won the best-actor Oscar for "The Theory of Everything." Industry veteran Julianne Moore, a five-time nominee, won her first Oscar for playing a patient struck with early-onset Alzheimer's disease in the film "Still Alice." "Birdman" director Alejandro Inarritu won the Oscar for best director, as well as best screenplay and best cinematography.
Sign-up for UPDATE: 'Birdman' wins four Oscars, including best picture investment picks
2015/2/23
By Russ Britt, MarketWatch Moore, Redmayne are top actors; 'Budapest' wins four awards LOS ANGELES (MarketWatch) -- "Birdman," the quirky tale of a Hollywood action hero's attempt to make a comeback via the Broadway stage, was declared the best picture of 2014 at Sunday's Academy Awards, taking four prizes in all and eking out a victory over "Boyhood." Eddie Redmayne, the British actor who took on the role of ALS-afflicted physicist Stephen Hawking, won the best-actor Oscar for "The Theory of Everything." Industry veteran Julianne Moore, a five-time nominee, won her first Oscar for playing a patient struck with early-onset Alzheimer's disease in the film "Still Alice." "Birdman" director Alejandro Inarritu won the Oscar for best director, as well as best screenplay and best cinematography.
Sign-up for 'Birdman' wins four Oscars, including best picture investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Gilead, CVS strike deal on Hepatitis C drugs to 'Birdman' wins four Oscars, including best picture
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent